Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD6001 with Tislelizumab and Bevacizumab in Advanced HCC and Solid Tumors
NCT05906524Phase 2Not yet recruiting
- Sponsor
- Shanghai Kanda Biotechnology
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of KD6001 in hepatocellular carcinoma (HCC), solid tumor, sponsored by Shanghai Kanda Biotechnology. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
KD6001
03
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT05906524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906524.